136 related articles for article (PubMed ID: 35525875)
1. A mild course of COVID-19 infection in a generalized Myasthenia gravis patient under eculizumab treatment.
Alis C; Emre DH; Karaali Savrun F; Gunduz A; Uzun Adatepe N
Neurol Sci; 2022 Sep; 43(9):5185-5187. PubMed ID: 35525875
[No Abstract] [Full Text] [Related]
2. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y
Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770
[TBL] [Abstract][Full Text] [Related]
3. [Eculizumab led to beneficial clinical course in a patient with generalized myasthenia gravis who developed COVID 19-associated pneumonia].
Kuroda Y; Watanabe G; Satou K; Ono H; Tsukita K; Suzuki Y
Rinsho Shinkeigaku; 2024 Feb; 64(2):109-112. PubMed ID: 38281749
[TBL] [Abstract][Full Text] [Related]
4. Minimal Manifestations With Eculizumab Therapy in a Patient With Refractory Generalized Seropositive Myasthenia Gravis.
Abdulrazaq A; Smith R; Digala LP; Govindarajan R
J Clin Neuromuscul Dis; 2022 Mar; 23(3):170-173. PubMed ID: 35188923
[No Abstract] [Full Text] [Related]
5. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K;
J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
8. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
9. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
[TBL] [Abstract][Full Text] [Related]
12. Managing Myasthenia Gravis with Eculizumab Monotherapy Through Pregnancy.
Li X; Mehrabyan A
Can J Neurol Sci; 2023 Sep; 50(5):803-805. PubMed ID: 35912546
[No Abstract] [Full Text] [Related]
13. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
[TBL] [Abstract][Full Text] [Related]
14. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab for the treatment of myasthenia gravis.
Mantegazza R; Cavalcante P
Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
18. Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report.
Strano CMM; Sorrenti B; Bosco L; Falzone YM; Fazio R; Filippi M
J Neurol; 2022 Nov; 269(11):6152-6154. PubMed ID: 35705882
[No Abstract] [Full Text] [Related]
19. Eculizumab as a promising rescue therapy for acute exacerbations of myasthenia gravis.
Kim S; Lee JJ; Seok HY
Neurol Sci; 2023 Dec; 44(12):4573-4574. PubMed ID: 37537418
[No Abstract] [Full Text] [Related]
20. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
